Irosustat is an orally available irreversible steroid sulfatase (STS) inhibitor.
According to futility analysis, the trial will not meet the primary endpoint and the superiority will not be demonstrated with Irosustat versus megestrol acetate in terms of progression free survival (PFS).
The primary endpoint for the study was the proportion of patients who have neither progressed nor died after 6 months of treatment with Irosustat.
The company has now agreed to investigate Irosustat (BN 83495) in conjunction with other hormonal therapies in hormone-dependent cancers.